References
- Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
- Bangham AD. Properties and uses of lipid vesicles: an overview. Ann N Y Acad Sci. 1978;308:2–7.
- Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–999.
- Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. New Engl J Med. 2015;373:1021–1031.
- Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (London, England). 2013;8:1509–1528.
- Fahr A, Seelig J. Liposomal formulations of cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst. 2001;18:141–172.
- Ishii F, Takamura A, Ishigami Y. Procedure for preparation of lipid vesicles (liposomes) using the coacervation (phase separation) technique. Langmuir. 1995;11:483–486.
- The Japanese Pharmacopoeia 16th Edition. 2011. The Ministry of Health, Labour and Welfare.
- Lim WY, Messow CM, Berry C. Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. Br J Pharmacol. 2012;165:2034–2043.
- Maherani B, Arab-Tehrany E, R Mozafari M, et al. Liposomes: a review of manufacturing techniques and targeting strategies. Curr Nanosci. 2011;7:436–452.
- Malaekeh-Nikouei B, Jaafari MR, Tabassi SA, Samiei A. The enhancement of immunosuppressive effects of cyclosporine A on human T-cells using fusogenic liposomes. Colloids Surf B Biointerfaces. 2008;67:238–244.
- Meure LA, Foster NR, Dehghani F. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech. 2008;9:798–809.
- Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005;10:711–719.
- Okuda K, Fu HY, Matsuzaki T, et al. Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats. PLoS One. 2016;11:e0160944.
- Ottani F, Latini R, Staszewsky L, et al. Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 2016;67:365–374.
- Patil YP, Jadhav S. Novel methods for liposome preparation. Chem Phys Lipids. 2014;177:8–18.
- Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New Engl J Med. 2008;359:473–481.
- Saegusa K, Ishii F. Triangular phase diagrams in the phospholipid-water-alcohol system for the preparation of lipid vesicles (liposomes) using the coacervation technique. Langmuir. 2002;18:5984–5988.
- Stability Testing of New Drug Substances and Products. 2003. The Pharmaceuticals and Medical Devices Agency.
- Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol. 2009;53:709–717.
- Takahama H, Shigematsu H, Asai T, et al. Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc Drugs Ther. 2013;27:125–132.
- The United States Pharmacopeia. 2014. The U.S. Pharmacopeial Convention.
- Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J Drug Deliv. 2011;2011:591325.
- Yu J, Anchordoquy TJ. Synergistic effects of surfactants and sugars on lipoplex stability during freeze-drying and rehydration. J Pharm Sci. 2009;98:3319–3328.